Natraceutical closed the first quarter of 2013 with a net profit growth of 38%, to 2.88 M€
- Turnover stood at 10.74 M€, a growth of 13.4% over the first quarter of 2012.
- Forté Pharma’s growth in sales and the operating optimization conducted over the past two years contributed to an EBITDA growth of 62.4% to 2.94 M€, which lead to an EBITDA margin increase from 19.1% to 27.4%.
- The cancellation of the syndicated loan in December 2012 allowed the company to eliminate the financial costs related to that debt, of around 1.1 M€ per quarter, and to incorporate financial gains from the significant cash position after the divestment of the shareholding stake in Naturex.
- The board of directors of Natraceutical agreed at its meeting yesterday in convening a general shareholders’ meeting for the upcoming May 30 and submit for the approval of said board, among other issues, a dividend distribution for an overall 12 M€.